Great Entry below 2 imo for 1 year hold ZTlido is a branded, non-aqueous, topical lidocaine patch for pain associated with post-herpetic neuralgia › Benefits vs. market leader, Lidoderm®, and other pain patches o Thin, pliable non-aqueous patch w/ 36 mg of drug to deliver therapeutic dose vs. Lidoderm, a thick, aqueous patch w/ 700 mg of drug to deliver therapeutic dose o Greater adhesion to the skin based on multiple adhesion studies ̶ 90% adhesion in 90% of subjects over 12 hours (no marketed patches have such data) ̶ No meaningful impact to PK during and after exercise o Less drug required to administer therapeutic dose, provides cost advantage in a largely genericized market › US pain patch market(1) = ~$700mm in 2015 o Potential tailwind from significant demand for abuse-deterrent alternatives for pain management › NDA resubmission expected in mid 2017, with potential approval in 2H17 (2 to 6 month review) http://sorrentotherapeutics.com/wp-content/uploads/2017/03/Sorrento-Corporate-Presentation-ROTH-Mar-2017-FINAL.pdf
|
|
|